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Optimum efficacy is the primary goal for any cancer therapy, and entails controlling tumour growth and prolonging survival as far as
possible. The prognosis for patients with metastatic renal cell carcinoma (mRCC) has greatly improved with the introduction
of targeted therapies. This review examines the development and efficacy of targeted agents for the management of mRCC, the
challenges offered by their rapid emergence, and discusses how mRCC treatment may evolve in the future. Improvements in
progression-free survival and overall survival rates, observed with targeted agents, indicate that it may now be possible to change
mRCC from a rapidly fatal and largely untreatable condition into a chronic disease. The major challenges to further advances in
targeted therapy for mRCC include overcoming drug resistance, identifying the most effective sequence or combination of targeted
agents, optimising clinical trial design and managing the cost of treatment.
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Renal cell carcinoma (RCC) accounts for almost 2% of all adult
malignancies (Parkin et al, 2005). There are 210000 new cases
diagnosed in the world each year, with more than 63000 of these
being in Europe (Parkin et al, 2005; Ferlay et al, 2007). Worldwide
and in Europe, the annual number of deaths from this disease are
100000 and 26000, respectively (Ferlay et al, 2007). At diagnosis,
approximately 20–30% of patients have metastatic renal cell
carcinoma (mRCC) (Motzer et al, 1996), and a similar percentage
of those with initially localised disease will subsequently relapse
and develop metastases (Antonelli et al, 2007).
Historically, cytokine therapy was the only systemic treatment
that had any consistent activity in mRCC. However, whereas
cytokine treatment, particularly high-dose interleukin 2, can be
associated with complete and durable responses, these occur in
only a small proportion of patients (Fisher et al, 2000). In addition,
cytokine treatment can be associated with substantial toxicity. In a
Cochrane review of interferon-a (IFN-a) for mRCC, median overall
survival (OS) for patients treated with this cytokine was found to
be 11.4 months, which represented a 3.8-month improvement
when compared with patients who received no immunotherapy
(Coppin et al, 2004). In a randomised phase III study, a median OS
of 17.5 months was observed in patients with mRCC, receiving
high dose interleukin-2 (IL-2), compared with 13 months, for those
treated with a combination of lower dose of IL-2 and IFN-a,
but this difference was not statistically significant (P¼0.211)
(McDermott et al, 2005). In addition, it has become clear that only
patients with good prognostic features are likely to benefit from
immunotherapy. This is further supported by the recent results of
McDermott et al (2010) who demonstrated a higher response rate
in patients, who were selected based on clinical and pathological
features, treated with high-dose IL-2 when compared with
historical data (28 vs 14%; P¼0.0016).
The development of targeted agents for the treatment of mRCC
has provided physicians with unprecedented opportunities to
improve clinical outcomes for patients with mRCC. For example,
compared with IFN-a, treatment, the oral multi-targeted receptor
tyrosine kinase (RTK) inhibitor, sunitinib malate (Sutent; Pfizer
Inc., New York, NY, USA) doubled median progression-free
survival (PFS) in a phase III trial of patients with previously
untreated mRCC (Motzer et al, 2007). In addition, sunitinib was
associated with median OS of greater than 2 years in this trial and
substantial improvements in objective response rates when
compared with IFN-a treatment (Motzer et al, 2007, 2009).
Optimum efficacy is the primary goal of any cancer treatment
and this means controlling tumour growth as far as possible and
prolonging survival. The new-targeted agents such as sunitinib,
with their improved response and survival rates, have allowed
this goal to be realisable for patients with mRCC. We now have
the therapeutic tools that could potentially result in mRCC
changing from a rapidly fatal, largely untreatable condition, into
a chronic disease. Several treatment challenges must be overcome
by us to maximise the potential of targeted agents, and these
include the identification of predictive molecular markers, drug
resistance, the identification of the most effective sequence or
combination of targeted agents, efficient clinical trial design
and the provision of cost-effective access to treatment for all
patients with mRCC.
This review examines the development and efficacy of targeted
agents for the management of mRCC, discusses the challenges
offered by their rapid emergence and speculates how mRCC
treatment might evolve in the future.
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Advances in our understanding of the molecular mechanisms
associated with RCC have enabled rational targets for systemic
therapy to be identified. In clear cell RCC, inactivation of the
von Hippel-Lindau gene is associated with the accumulation of
both hypoxia-inducible factor 1 (HIF-1a) and HIF-2a. HIF-1a
causes transcriptional activation of several genes, including
vascular endothelial growth factor (VEGF) and platelet-derived
growth factor (PDGF), both of which are implicated in tumour
angiogenesis and growth (Krause and Van Etten, 2005). These
ligands serve as agonists for their respective RTKs, VEGF receptor
(VEGFR) and PDGF receptor (PDFGR). HIF-1a activity is also
regulated by other growth factor and cell adhesion pathways
(Motzer and Bukowski, 2006); for example, HIF-1a is increased in
response to growth factor binding to the phosphatidylinositol 3-
kinase/Akt/mammalian target of rapamycin (mTOR) and Ras/Raf/
mitogen-activated protein kinase signalling pathways. In contrast,
HIF2-a has an opposing role to HIF-1a with regard to gene
expression, and promotes enhanced tumour growth (Toschi et al,
2008; Biswas et al, 2010). Elevation of HIF2-a expression also
contributes towards angiogenesis (Toschi et al, 2008).
The formation of a multi-molecular complex between mTOR
and regulatory-associated protein of mTOR (raptor) has a role in
cell proliferation, survival and tumour angiogenesis (Le Tourneau
et al, 2008). Upregulation of VEGF or PDGF can also stimulate
activity of mTORC1 (Le Tourneau et al, 2008). In addition, mTOR
is also able to form a complex with rapamycin-insensitive
companion of mTOR (rictor) to form mTORC2 (Le Tourneau
et al, 2008). Development of targeted therapies has focused on
mTORC1 and other components of the HIF-1a signalling pathway,
aimed at reducing the effects of growth factors, including VEGF
and PDGF.
Sunitinib is a multi-targeted RTK inhibitor, targeting a range of
receptors including VEGFR-1, -2 and -3, PDGFR-a and -b, glial cell
line-derived neurotrophic factor receptor (REarranged during
Transfection; RET), the receptor for macrophage colony-stimulat-
ing factor 1, FMS-like tyrosine kinase 3 receptor (FLT3) and c-KIT
(Motzer et al, 2007). Sorafenib (Nexavar; Bayer Healthcare,
Leverkusen, Germany) and pazopanib (Votrient; GlaxoSmithKline,
Middlesex, UK), are also both oral multi-targeted RTK inhibitors,
with sorafenib targeting VEGFR-2 and -3, PDGFR-b, FLT3, c-KIT,
RET, B-Raf and Raf-1/C-Raf (Escudier et al, 2009a) and pazopanib
targeting VEGFR-1, -2 and -3, PDGFR-a and -b and c-KIT
(Sternberg et al, 2010a). Temsirolimus (Torisel; Pfizer Inc) and
everolimus (Afinitor; Novartis, Basel, Switzerland) are both mTOR
kinase inhibitors (Hudes et al, 2007; Motzer et al, 2008) and
bevacizumab (Avastin; F Hoffmann-La Roche, Basel, Switzerland)
is a humanised monoclonal antibody that binds to and neutralises
all major isoforms of VEGF-A (Escudier et al, 2010a).
Sunitinib is approved multinationally for the treatment of mRCC,
a n di sar e f e r e n c es t a n d a r do fc a r ef o rt h ef i r s t - l i n et r e a t m e n to f
patients with mRCC (Escudier et al, 2010b). Other targeted agents
that are approved in the first-line setting include temsirolimus for
the treatment of mRCC patients, with poor prognostic factors, and
the combination of bevacizumab plus IFN-a. Sorafenib is approved
for patients with mRCC who have failed, or are considered
unsuitable for, cytokine therapy. Everolimus is approved for the
treatment of patients with mRCC following the failure of treatment
with sunitinib or sorafenib (Escudier et al, 2010b). Most recently,
pazopanib has been approved in the USA for the treatment of
advanced RCC, and received conditional approval in Europe for the
treatment of advanced RCC in the first-line setting and in patients
with previous cytokine therapy. In contrast to sunitinib, sorafenib
and pazopanib, temsirolimus and bevacizumab both have single
targets and are administered intravenously. Everolimus also has a
single target, but is orally administered.
Additional targeted agents are currently under investigation for
mRCC. Those in phase III of development include axitinib, an
orally administered multi-targeted receptor RTK inhibitor (Rini
et al, 2007; Rixe et al, 2007) and tivozanib, an oral VEGFR-targeted
tyrosine kinase inhibitor (Bhargava et al, 2009). Both these agents
are similar in terms of mechanisms of action to the currently
available VEGF-targeted therapies, and differ from these agents on
the basis of affinities for the various receptors (Eskens et al, 2008;
Schmidinger and Bellmunt, 2010). The clinical efficacy demon-
strated by the targeted agents approved for the treatment of
mRCC, and the most promising of those currently in development,
are summarised in Tables 1–3.
TARGETED AGENTS AND DRUG RESISTANCE
Targeted agents have significantly improved the prognosis for
patients with mRCC; however, complete responses are rare
and the majority of patients develop drug resistance, as
exemplified by the fact that their disease progresses during
treatment (Sosman et al, 2007). Drug resistance is the underlying
reason for the growth and spread of tumours in the presence of
systemic treatment, and it is the main barrier against long-term
tumour control.
Table 1 Clinical efficacy data for targeted agents approved in Europe/USA for the treatment of mRCC in the first-line setting
Number of
patients (N)
Median PFS
(months) P-value
Median OS
(months) P-value
Sunitinib (Motzer et al, 2009) 375 11 o0.001 26.4 0.051
vs IFN-a 360 5 21.8 0.049
a
Temsirolimus
w (Hudes et al, 2007) 209 5.5 0.0001 10.9 0.0069
vs IFN-a 207 3.1 7.3
Bevacizumab (plus IFN-a) (Escudier et al, 2010a) 327 10.2 o0.0001 23.3 0.1291
vs IFN-a 322 5.4 21.3
Bevacizumab (plus IFN-a) (Rini et al, 2009b, 2010b) 369 8.5 o0.0001 18.3 0.069
vs IFN-a 363 5.2 17.4
Sorafenib (Escudier et al, 2009b) 97 5.7 0.504 NR NA
vs IFN-a 92 5.6
Pazopanib (Sternberg et al, 2010a,b) (overall) 290 9.2 o0.0001 22.9 0.224
vs placebo (overall) 145 4.2 20.5
Treatment-naı ¨ve patients 155 11.1 o0.0001 NR NA
vs placebo 78 2.8
Abbreviations: IFN-a¼interferon-alfa; NA¼not applicable; NR¼not reported; OS¼overall survival; PFS¼progression-free survival.
aP-values by pre-planned unstratified and
stratified log-rank test, respectively.
wPatients stratified into the poor-risk prognostic category on the basis of three of six risk features (five pre-defined Memorial Sloan–Kettering
Cancer Centre risk factors plus multiple sites of organ metastases).
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result of the multiplicity of pathways involved in regulating
HIF-1a activity, some of which have not yet been identified. A
particular targeted agent may effectively inhibit one or more
pathways, but resistance can result from the development of other
molecular and cellular processes that ‘bypass’ this effect (Figure 1).
These include additional mutations, feedback loops compensating
for inhibition through gene upregulation, increased angiogenesis
or the activation of downstream mediators (Sosman et al, 2007).
Furthermore, some of these bypass mechanisms may not even
involve the VEGF pathway. For example, a preclinical study
demonstrated that upregulation of proangiogenic pathways,
through increased expression of IL-8, contributed towards evasion
of anti-angiogenic effects mediated by sunitinib (Huang et al,
2010).
Rini and Flaherty (2008) have described three clinical patterns of
resistance in patients with mRCC: a small group (15–20%), which
is resistant to therapy from the outset of treatment, a larger group
that demonstrates early-tumour regression followed by a short
period of stability then disease progression (6–12 months from the
start of therapy) and finally a subgroup of patients that exhibit
tumour response over several months followed by a prolonged
period of stable disease, without the appearance of new lesions.
Additional reasons for the development of resistance to
treatment may include pharmacokinetic resistance to treatment
whereby the pharmacokinetic activity of the treatment may
be affected by interaction with cellular proteins or structure such
as transport pumps (Schmidt, 2008). Non-compliance with oral
treatment may also result in the development of resistance to
treatment (Schmidt, 2008).
The mode of action of targeted agents will affect the strategies
that will be utilised to overcome drug resistance. Multi-targeted
agents may provide the most effective option for combating drug
resistance because of involvement of multiple signalling pathways
in the pathology of RCC. Differential responses to targeted agents
have been observed between tumours within the same patient, and
also between tumours within the same organ. This indicates
Table 2 Clinical efficacy data for targeted agents approved in Europe/USA for the treatment of mRCC in the second-line setting
Number of
patients (N)
Primary
treatment
Median PFS
(months) P-value
Median OS
(months) P-value
Sorafenib (Escudier et al, 2009a) 451 Systemic therapy with cytokines 5.5 o0.001 17.8 0.0287
vs placebo 452 2.8 14.3
Everolimus (Escudier et al, 2008; Motzer et al, 2009, 2010)
(overall)
272 Previous VEGF inhibitor therapy
(sunitinib, sorafenib or both;
bevacizumab permitted);
systemic therapy with cytokines
4.9 o0.001 14.8 0.177
vs placebo (overall) 138 1.9 14.4
refractory to sunitinib 124 3.9 o0.001 NR NA
vs placebo 60 1.8
refractory to sorafenib 77 5.9 o0.001 NR NA
vs placebo 42 2.8
Pazopanib (Sternberg et al, 2010a,b) (overall) 290 Previous systemic therapy
with cytokines
9.2 o0.0001 22.9 0.224
vs placebo (overall) 145 4.2 20.5
cytokine-pre-treated patients 135 7.4 o0.001 NR NA
vs placebo 67 4.2
Abbreviations: NA¼not applicable; NR¼not reported; OS¼overall survival; PFS¼progression-free survival.
Table 3 Clinical efficacy data for targeted agents in development for the treatment of mRCC
Study design
Median PFS
(months) P-value
Median OS
(months) P-value
Reyorafenib (Eisen et al, 2009) First line, phase II 8.3 NA NR NA
Tivozanib (Bhargava et al, 2009) First line, phase II 11.8 NA NR NA
Axitinib (Rixe et al, 2007) Second line, phase II 15.7
a NA 29.9 NA
Axitinib (Rini et al, 2007; Dutcher et al, 2008) Second line, phase II 7.4 NA NR NA
Refractory to sunitinib and sorafenib 7.1
Refractory to cytokines and sorafenib 9
Refractory to sorafenib 7.7
Linifanib (Tannir et al, 2009) Second line, phase II 5.4 NA 15.7 NA
Cediranib (Mulders et al, 2009) First/second line, phase II 12.1 0.017 NR NA
vs placebo 2.8
Abbreviations: NA¼not applicable; NR¼not reported; OS¼overall survival; PFS¼progression-free survival.
aReported as time to progression.
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Figure 1 Resistance to targeted agents may occur through target bypass
mechanisms. A targeted agent (denoted by X in the figure) may effectively
inhibit the signalling cascade of one or more pathway (denoted by the light
grey square and circle in the figure). However, the presence of a ‘bypass’
mechanism may allow this inhibition to be circumvented by signalling along
an unknown or unrelated pathway (denoted by the light grey triangle in the
figure), resulting in resistance to the targeted therapy.
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multi-targeted agents, such as sunitinib or sorafenib, instead
of single-targeted agents, might be most effective at simultaneously
blocking, both known and unknown, angiogenic and proliferation
pathways.
A major consideration in devising the optimal treatment
strategy to overcome drug resistance, and thus optimising long-
term therapy with targeted agents in mRCC is how best to use
these agents in sequence or in combination. Data in favour
of either sequencing or combining targeted agents for mRCC are
currently limited, and as discussed below, clinical studies are
ongoing to investigate both these approaches.
SEQUENTIAL THERAPY WITH TARGETED AGENTS
Targeting different pathways through sequential therapy should
offer benefit in terms of overcoming resistance to individual
agents. It also enables a treatment continuum to be achieved,
maintaining patients on treatment without progression for as long
as possible. Sequential therapy has the potential to change mRCC
into a chronic disease that can be managed for long term through
the administration of targeted agents in sequence. It should also
enable full dosages of targeted agents to be administered, ensuring
that optimal drug levels are achieved without the additional
toxicity that often occurs with combinatorial approaches. There is
emerging evidence that dose is important with the targeted
agents in this disease. The results of a meta-analysis of data
from sunitinib studies indicated that higher sunitinib exposure is
associated with higher efficacy with respect to longer times to
tumour progression and OS (Houk et al, 2010). In practice,
clinicians are currently using targeted agents in a sequential
manner for patients with mRCC, although concerns remain
regarding cross-resistance between the different agents, and there
are many questions regarding the optimal sequence for obtaining
maximal clinical benefit from the available targeted therapies.
Current data indicate that there is a degree of non-cross-
resistance between the different targeted agents. A retrospective
study by Tamaskar et al (2006) found that both sunitinib and
sorafenib demonstrated anti-tumour activity in patients refractory
to previous anti-angiogenic therapy. In particular, clinical benefit
was observed in patients receiving sorafenib following previous
therapy with sunitinib and vice versa. Similarly, a lack of cross-
resistance between sunitinib and sorafenib was observed in
another retrospective analysis of 90 patients, supporting sequential
use of these agents in the treatment of mRCC (Sablin et al, 2007).
The results of a randomised phase II study of sorafenib alone and
in combination with low-dose IFN-a following previous first-line
sunitinib treatment in patients with mRCC are awaited (CONCERT
study) (http://www.clinicaltrials.gov).
Incomplete cross-resistance has also been demonstrated
between sunitinib and bevacizumab. Rini et al (2008) treated
61 bevacizumab-refractory patients with sunitinib; an objective
response rate of 23% (95% CI: 13.2–35.5) and median PFS of 30.4
weeks (95% CI: 18.3–36.7) were achieved. All these data suggest
that resistance to one VEGF-targeted therapy can be overcome
by another agent that also targets this pathway.
Interestingly, transient resistance to the same agent has also
been observed. In a recent retrospective review of 23 patients,
re-challenge with sunitinib in patients with disease progression on
sunitinib and other therapies, resulted in 5 patients (22%)
achieving PR and 17 patients (74%) achieving SD (Rini et al,
2010a). Re-challenge was associated with a median PFS of 7.2
months compared with 13.7 months on initial treatment (P¼0.04).
In addition, patients with more than 6 months between sunitinib
treatments had significantly longer PFS than those receiving
re-treatment with sunitinib within 6 months (16.5 and 6.0 months,
respectively). The results described here indicate the potential for
re-treating with an agent despite the occurrence of resistance at
first treatment and have implications for achieving a continuum
of treatment in these patients.
The first randomised phase III study to investigate sequential
targeted therapy in mRCC showed clinical efficacy for the sequence
of sunitinib or sorafenib, followed by everolimus (RECORD-1)
(Escudier et al, 2008; Motzer et al, 2008, 2010). In this study,
patients who had failed earlier anti-VEGF therapy, 71% of
whom had received sunitinib previously, were treated with either
everolimus or placebo. The median PFS was 4.9 vs 1.9 months for
those treated with everolimus or placebo, respectively (Po0.001;
hazard ratio (HR) 0.33 (95% CI: 0.25–0.43)). Improvements in PFS
with everolimus relative to placebo were observed across all
Memorial Sloan–Kettering Cancer Center (MSKCC) prognostic
risk groups. Patients pre-treated with sunitinib achieved a median
PFS of 3.9 vs 1.8 months when treated with everolimus or placebo,
respectively (Po0.001; HR 0.34 (95% CI: 0.23–0.51)). Everolimus-
treated sorafenib-refractory patients achieved a median PFS of 5.9
vs 2.8 months for those treated with placebo (Po0.001; HR 0.25
(95% CI: 0.16–0.42)). Patients refractory to both sunitinib and
sorafenib achieved a median PFS of 4.0 months when treated
with everolimus compared with 1.8 months for those treated with
placebo (Po0.001; HR 0.32 (95% CI: 0.19–0.54)).
Sequential treatment has also been investigated with the VEGF
inhibitor, axitinib. In a phase II study, median PFS was 7.1, 9.0,
and 7.7 months for those mRCC patients who had received
previous treatment with sunitinib and sorafenib, cytokines and
sorafenib, or sorafenib alone, respectively (Dutcher et al, 2008).
The phase III AXIS study investigates axitinib in 540 patients with
mRCC who have experienced failure on a first-line treatment,
including sunitinib, bevacizumab plus IFN-a, temsirolimus
or cytokines (http://www.clinicaltrials.gov). A phase III study
comparing sorafenib with temsirolimus (INTORSECT study) will
also investigate sequential therapy in an estimated 440 patients
who have failed first-line sunitinib (Bhojani et al, 2008).
In the context of sequential therapy, adequate management
of treatment-related toxicity can allow patients to remain on
treatment for long periods and help maximise the clinical
benefit of targeted agents. The toxicity profile of each of the
targeted agents approved for the treatment of mRCC is well
defined (Figure 2), and strategies to manage treatment-related
adverse events are being refined (Bhojani et al, 2008). In addition,
clinicians’ familiarity with targeted agents is increasing and this
experience is accompanied by the ability to manage treatment-
related adverse events more effectively. Effective therapy
management involves optimisation of dose, maximising treatment
duration and a proactive approach to the management of
toxicities.
COMBINATION THERAPY WITH TARGETED AGENTS
Combining therapeutic agents may also overcome drug resistance
and allow for the simultaneous inhibition of multiple signalling
pathways. These combinations could consist of agents blocking a
single target, single and/or multi-targeted agents, and targeted
agents combined with cytotoxics, cytokines or other therapeutic
agents. This approach presupposes knowledge of all the signalling
pathways involved in the development and continuing growth of a
tumour. Furthermore, any potential clinical benefit must be
balanced against the potential increase in toxicity associated with
combining therapeutic agents.
Combination therapies are currently under investigation in
several ongoing and planned clinical trials. These include several
studies evaluating bevacizumab in combination with temsirolimus,
everolimus and sorafenib (Merchan et al, 2007; Sosman et al, 2008;
Whorf et al, 2008). Two phase I studies have evaluated sunitinib in
combination with bevacizumab for the treatment of solid tumours,
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from these studies have noted that the combination is associated
with significant toxicity at full-doses of sunitinib and bevacizumab
(Feldman et al, 2007; Rini et al, 2009a). Similarly, treatment of
patients with mRCC using sorafenib in combination with
bevacizumab does not seem to be possible at full doses of both
drugs (Sosman et al, 2006). A further phase I study, in which
temsirolimus was combined with sunitinib, was terminated
because of dose-limiting toxicity observed at low-starting doses
of both agents (Patel et al, 2009). Sorafenib plus IFN-a2b
demonstrated clinical activity for the first-line treatment of
patients with mRCC, but the toxicity profile of this combination
has limited its development in relation to the use of full doses of
both these agents within such a combination (Ryan et al, 2007).
Another study, evaluating the efficacy of bevacizumab combined
with everolimus demonstrated clinical activity of the combination
for the treatment of patients with advanced RCC, although the
efficacy results did not demonstrate a clear advantage for
the combination over single agent, sequential treatment and the
occurrence of grades 3–4 proteinuria was higher than expected in
this study (Hainsworth et al, 2010). The results of these early
studies demonstrate the potential for detrimental effects for the
combination of therapeutic agents. Further larger studies are
required to determine the clinical applicability if any, of other
targeted agent combinations.
It is also important to consider the therapeutic options that are
possible or available following the use of combination-targeted
agent therapy. The development of resistance to combination-
targeted therapy could negatively impact subsequent treatment.
This theoretical consideration relates to the possibility that
combination therapy will ‘use’ up active treatment options,
and denies the potential for the repeated ‘beneficial’ interventions
that the single-agent sequential therapy strategy affords (Figure 3).
TARGETED AGENTS AND CLINICAL TRIAL DESIGN
The approval of sunitinib, sorafenib, temsirolimus, everolimus,
bevacizumab plus IFN-a and pazopanib in Europe for the
treatment of mRCC, resulted in the establishment of evidence-
based recommendations and a treatment algorithm that can be
used to achieve optimal clinical benefit with these agents. Data
from randomised phase III clinical trials were, of course, an
essential element in this process (Escudier et al, 2010b).
A large number of new targeted therapeutic compounds
are currently under investigation for mRCC. Using traditional
‘pick the winner’ trials to demonstrate the efficacy of these agents
in mRCC could result in the failure of some compounds, as current
trial designs and statistical methods may not be sensitive enough
to evaluate their therapeutic benefits, particularly as they relate to
subgroups of mRCC patients, for example, those with comorbid-
ities, histological and molecular subtypes.
In addition, the end points used in phase II and III clinical trials
might not always be appropriate for assessing the efficacy of new
agents (Medina et al, 2007). Standard cytotoxic agents rely on
response rates, time to tumour progression, PFS and OS as clinical
end points to assess efficacy. Targeted therapies may have both
a cytotoxic and a cytostatic effect, complicating assessment
of response to treatment. As such, clinical benefit consisting of a
partial response and/or disease stabilisation, that is, ‘slowing’ of
disease progression could be a clinically relevant new parameter of
efficacy. It is this concept, together with the strategy of single-agent
sequential therapy, which could transform mRCC into a chronic
condition (Figure 3). The most appropriate end points for
assessing efficacy of new targeted agents are currently under
debate. Biomarkers serving as surrogates for efficacy, functional
imaging technology and a focus on new clinical end points, are all
required to help further develop this area of novel therapeutics
(Medina et al, 2007; Sessa et al, 2008).
Biomarkers may identify patients with the potential to benefit
from targeted therapy, and may be predictive of response, allowing
a more individualised approach to prognostication and treatment.
The expression of several molecular markers, including circulating
VEGF, endostatin and cell surface markers, such as CD31, may all
be relevant in this context (Sessa et al, 2008). These biomarkers
may be useful in predicting treatment outcomes in mRCC, but they
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Figure 3 Treatment strategies with targeted agents involve a sequential
or a combinatorial approach; single-agent sequential therapy may cause
tumour shrinkage but may also slow disease progression and, therefore,
turn mRCC into a chronic disease.
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Figure 2 Most common and side effects of interest reported with the six licensed targeted agents for mRCC.
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Imaging studies can also contribute towards determining the
efficacy of an agent under development, providing useful
information regarding early-treatment response by monitoring
alterations in tumour vasculature and angiogenesis (Sessa et al,
2008). However, the implementation of multiple assessments
for each patient could prove to be prohibitively costly (Sessa
et al, 2008).
ACCESS TO TARGETED AGENTS
Considerations of cost can impact the availability, timing and
duration of treatment with targeted therapies. It may also influence
the choice of treatment strategy used to overcome drug resistance
and how response to therapy is assessed. Commissioners and
providers of healthcare are increasingly looking to achieve the
most cost-effective outcomes by balancing clinical efficacy
against patient management costs, for example, costs of managing
adverse events and drug pricing. Recently, the cost-effectiveness of
sunitinib for the first-line treatment of patients with mRCC
was evaluated by the National Institute for Health and
Clinical Excellence (NICE) in the United Kingdom. The NICE
Assessment Group developed an analysis model to evaluate the
cost-effectiveness of sunitinib in comparison with IFN-a as well as
the other therapies approved for the treatment of mRCC, and
concluded that sunitinib provided a cost-effective option for the
treatment of patients with mRCC in the first-line setting.
The NICE finding mirrors the economic analyses conducted
using data from phase II and III trials of sunitinib,
sorafenib, bevacizumab plus IFN-a and temsirolimus vs IFN-a as
first-line therapy for patients with mRCC in the USA, Sweden
and Spain (Oudard et al, 2010). On the basis of indirect
treatment comparisons, these analyses identified sunitinib as a
cost-effective alternative to sorafenib, bevacizumab plus IFN-a and
temsirolimus in the first-line treatment of patients with mRCC.
Cost-effectiveness ratios of sunitinib vs other therapies were within
the established threshold that society is willing to pay for health
benefits.
CONCLUSION
The development of targeted agents has substantially improved the
prognosis for patients with mRCC and has the potential to convert
mRCC into a chronic disease.
Challenges in achieving this goal include:
  identifying and optimising the most appropriate sequence or
combination of agents.
  development of molecular biomarkers to better identify the
patients who are likely to benefit from a particular agent.
  imaging techniques as predictive markers of efficacy to
minimise the time on treatment for those patients who will
not respond to a particular agent.
  developing appropriate clinical trial designs and statistical
methods to test new therapies.
  overcoming drug resistance by more new agents, or sequential
or combination therapies.
  managing the cost barriers against treatment.
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